Navigation Links
Premier Healthcare Renews Supplier Agreement with Masimo
Date:6/7/2012

IRVINE, Calif., June 4, 2012 /PRNewswire/ -- Masimo (NASDAQ: MASI) announced today that it has been awarded a 33-month group purchasing renewal agreement with the Premier Healthcare Alliance, a leading national healthcare group purchasing organization. The new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for Masimo's complete market-leading line of noninvasive products and solutions, including Masimo SET® pulse oximetry, rainbow® SET Pulse CO-Oximetry,™ rainbow® Acoustic Monitoring™, and Masimo Patient SafetyNet™.

Masimo President of World Wide Sales, Marketing and clinical Research, Jon Coleman, stated, "We are happy Premier recognizes that blood transfusions represent a large cost in a hospital and has committed to providing its membership with access to Masimo rainbow® SET platform that enables clinicians to noninvasively and continuously measure total hemoglobin (SpHb®), along with many other vital parameters, to help clinicians improve blood management and advance the standard of care."

Effective June 1, 2012, through February 1, 2015, Premier members can purchase Masimo Radical-7®, Rad-87®, and portable Rad-57® and Pronto-7 rainbow SET Pulse CO-Oximeters, and Masimo Patient SafetyNet™ on contract, along with ReSposable, Single Patient Use Adhesive, and Reusable
'/>"/>

SOURCE Masimo
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology news :

1. Join GSA in Boston for the nations premier aging conference
2. Join GSA in New Orleans for the nations premier aging conference
3. Premier issue of new Childhood Obesity journal launched by Mary Ann Liebert Inc., publishers
4. Elsevier pilots new research tool Reflect in its premier life science journal Cell
5. Premier issue of Ecopsychology launched by Mary Ann Liebert Inc. publishers
6. World premiere in stem cell research in Montreal
7. New ecopsychology journal will premiere in spring 2009
8. Early Bird Offers on Healthcare and Biotechnology Conferences, Save Up To 20% by Registering with Global Information
9. Bioethics for Beginners: 60 Cases and Cautions from the Moral Frontier of Healthcare
10. Boston Healthcare Associates Roundtable Explores Challenges and Opportunities Surrounding the Value of Big Data within the Life Sciences
11. Early Bird Discounts Available on International Healthcare and Biotechnology Conferences, Save Up To $600 with Global Information
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... According to a new market ... Technology (Touch-based & Touchless), Application (Consumer Electronics, Automotive, & ... - Global Forecast to 2020", published by MarketsandMarkets, the ... reach $23.55 Billion by 2020, at a CAGR of ... 83 market data T ables and   86 ...
(Date:6/1/2015)... DALLAS , June 1, 2015 ... report "Next Generation Biometrics Market by Application (Government, ... Electronics, Travel & Immigration, and Security), Technology (Face ... Recognition, Signature Recognition, Vein Recognition, and Others), Function ... America , Europe , ...
(Date:5/29/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/2w6zgs/facial ... "Facial Recognition Market by Solution, by Software, by ... 2020" report to their offering. ... technology become more efficient and cost effective. This ... investment from the commercial sector. The development of ...
Breaking Biology News(10 mins):Gesture Recognition & Touchless Sensing Market Worth $23.55 Billion by 2020 2Gesture Recognition & Touchless Sensing Market Worth $23.55 Billion by 2020 3Gesture Recognition & Touchless Sensing Market Worth $23.55 Billion by 2020 4Next Generation Biometrics Market Worth $24,448.84 Million by 2020 2Next Generation Biometrics Market Worth $24,448.84 Million by 2020 3Next Generation Biometrics Market Worth $24,448.84 Million by 2020 4Global advanced Facial Recognition Market Expected to Grow From $2.77 Billion in 2015 to $6.19 Billion in 2020, at an Estimated CAGR of 17.4% 2
... GAINESVILLE, Fla. Survival of the fittest has popularly ... new study published in the Royal Society journal Biology ... millions of years may also play a powerful role. ... are the first to link the evolution of proteins ...
... Emory University School of Medicine a three-year grant of more ... that may contribute to the development of autism. Stephen ... Genetics, is principal investigator of the program project that also ... faculty members in human genetics. Autism occurs four ...
... research project, which receives funding from Hope Against ... an extract from bilberries can prevent or delay ... Gescher, of the University of Leicester, is ... with the commercially produced substance Mirtoselect (extracted from ...
Cached Biology News:UF researchers devise way to calculate rates of evolution 2UF researchers devise way to calculate rates of evolution 3Simons Foundation awards Emory scientists $3M for autism gene research 2Bilberry extract -- can it help prevent certain cancers? 2Bilberry extract -- can it help prevent certain cancers? 3
(Date:6/3/2015)... Global Stem Cells Group ... plans to conduct Turkey’s first ever stem cell harvesting ... his alliance with Stem Cell Training, Inc. and in ... Tiryaki, M.D. will conduct the Adipose and Bone ... Istanbul. , Tiryaki, a renowned plastic surgeon practicing in ...
(Date:6/3/2015)... 02, 2015 Research and Markets ... of the "2015 Strategies in the ... to their offering. This new ... immunoprotein diagnostic market, including emerging tests, technologies, ... profiles of leading suppliers. During ...
(Date:6/3/2015)... HOLLYWOOD, Calif. , June 3, 2015 ... of life of myeloma patients while working toward prevention ... Annual International Myeloma Working Group (IMWG) Summit June ... record 100-plus IMWG members will attend the 2015 Summit, ... of the European Hematology Association (EHA).  The focus of ...
(Date:6/3/2015)... 2015 Findings presented at the ... European Association of NeuroOncology (EANO) and European Society for ... demonstrate that EDO-S101 is effective in models of ... combination with radiotherapy (RT). [ 1 ] ... fusion molecule that combines the DNA damaging effect of ...
Breaking Biology Technology:Global Stem Cells Group subsidiary Stem Cell Training Announces First Training Course to Take Place in Turkey 2Global Stem Cells Group subsidiary Stem Cell Training Announces First Training Course to Take Place in Turkey 3United States Strategies in the Immunoprotein Diagnostic Testing Market Report 2015 2International Myeloma Foundation Brings Together 100 of the World's Top Myeloma Experts June 8-10 in Vienna, Austria for 6th Annual Summit 2International Myeloma Foundation Brings Together 100 of the World's Top Myeloma Experts June 8-10 in Vienna, Austria for 6th Annual Summit 3International Myeloma Foundation Brings Together 100 of the World's Top Myeloma Experts June 8-10 in Vienna, Austria for 6th Annual Summit 4Mundipharma EDO GmbH Data Confirm EDO-S101 is Effective in Preclinical Models of Human Glioblastoma 2Mundipharma EDO GmbH Data Confirm EDO-S101 is Effective in Preclinical Models of Human Glioblastoma 3Mundipharma EDO GmbH Data Confirm EDO-S101 is Effective in Preclinical Models of Human Glioblastoma 4
... , ... ... ... ...
... ... with a Complete, Cloud-Enabled API for Developers , ... Westborough, Mass. (Vocus) March 4, 2010 -- This seminar details the fast-growing ... The free seminar will include lunch, discussion, and startup to Free Basic Account. , ...
... ... ... ... ...
Cached Biology Technology:OncoGenex Pharmaceuticals to Webcast Discussion of Financial Results for Fourth Quarter and Fiscal Year 2009 2OncoGenex Pharmaceuticals to Webcast Discussion of Financial Results for Fourth Quarter and Fiscal Year 2009 3GenomeQuest Hosting Seminar at X Gen Congress In San Diego 2GenomeQuest Hosting Seminar at X Gen Congress In San Diego 3Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 2Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 3Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 4Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 5Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 6Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 7Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 8Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 9Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 10Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 11Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 12Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 13Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 14Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 15Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 16Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 17Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 18Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 19Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 20Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 21Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 22Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 23Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 24Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 25Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 26Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 27Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 28Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 29Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 30Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 31Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 32
... Xylene Resistant (X/R) Red System consists ... Red Activator and X/R Red Buffer. ... alkaline phosphatase to produce red staining ... ,Kit Contains:, , Buffer, 100 mL ...
Phospho-YAP (Ser127) Antibody Ship: Hot Store: -20 C...
Mouse Cell Line Slides...
... comprehensive, cost-effective solution to your TechMate ... quality into both our products and ... chemistries and antibodies that have been ... also includes our competitively priced accessories ...
Biology Products: